Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators

• US 20020019330A1
• Filed: 12/15/2000
• Published: 02/14/2002
• Est. Priority Date: 08/11/1999
• Status: Abandoned Application

• Current Assignee: EOS Biotechnology, Inc. (PDL BioPharma, Inc.)
• Original Assignee: EOS Biotechnology, Inc. (PDL BioPharma, Inc.)
• Inventors: Murray, Richard, Hevezi, Peter, Weiss, Stephen J., Glynne, Richard, Watson, Susan
• Application Number:
  US09/738,873
• Publication Number:
  US 20020019330A1
• Time in Patent Office: Days
• US Class Current: 514/1
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/4725 Mucins, e.g. human intestinal mucin
• CPC Class Codes: G01N 2800/7014 (Neo)vascularisation - Angiogenesis
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/5064 Endothelial cells
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Described herein are methods that can be used for diagnosis of angiogenesis and angiogenic phenotypes. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate angiogenesis. Additionally, molecular targets (genes and their products) for therapeutic intervention in disorders associated with angiogenesis are described. Moreover, methods for using such molecular targets are described.

Claims

1. A method of screening drug candidates comprising:

a) providing a cell that expresses an expression profile gene encoding AAA9 or fragment thereof;

b) adding a drug candidate to said cell; and

c) determining the effect of said drug candidate on the expression of said expression profile gene.

2. A method according to claim 1 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.

3. A method of screening for a bioactive agent capable of binding to AAA9 or a fragment thereof, said method comprising:

a) combining said AAA9 or a fragment thereof and a candidate bioactive agent; and

b) determining the binding of said candidate agent to said AAA9 or a fragment thereof.

4. A method for screening for a bioactive agent capable of modulating the activity of AAA9, said method comprising:

a) combining AAA9 and a candidate bioactive agent; and

b) determining the effect of said candidate agent on the bioactivity of AAA9.

5. A method of evaluating the effect of a candidate angiogenesis drug comprising:

a) administering said drug to a patient having an angiogenesis disorder;

b) removing a cell sample from said patient; and

c) determining the expression of AAA9 or a gene encoding AAA9.

6. A method according to claim 5 further comprising comparing said expression of a gene encoding AAA9 or fragment thereof to expression of AAA9 in a healthy individual.

7. A method of diagnosing an angiogenesis disorder comprising:

a) determining the expression of a gene encoding AAA9 or a fragment thereof in a first tissue type of a first individual; and

b) comparing said expression of said gene from a second normal tissue type from said first individual or a second unaffected individual;

wherein a difference in said expression indicates that the first individual has an angiogenesis disorder.

8. An antibody which specifically binds to AAA9 or a fragment thereof.

9. The antibody of claim 8, wherein said antibody is a monoclonal antibody.

10. The antibody of claim 8, wherein said antibody is a humanized antibody.

11. The antibody of claim 8, wherein said antibody is an antibody fragment.

12. The antibody of claim 8, wherein said antibody modulates the bioactivity of AAA9.

13. The antibody of claim 12, wherein said antibody is capable of inhibiting the bioactivity or neutralizing the effect of AAA9.

15. A method according to claim 14, wherein said antibody is capable of inhibiting or neutralizing the bioactivity of AAA9.

17. A method according to claim 16 wherein said inhibitor is an antibody.

20. A method according to claim 19 wherein said inhibitor is an antibody.

14. A method for screening for a bioactive agent capable of interfering with the binding of AAA9 or a fragment thereof and an antibody which binds to AAA9 or fragment thereof, said method comprising:

a) combining AAA9 or fragment thereof, a candidate bioactive agent and an antibody which binds to AAA9 or fragment thereof; and

b) determining the binding of AAA9 or fragment thereof and said antibody.

16. A method for inhibiting the activity of AAA9, said method comprising binding an inhibitor to AAA9.

18. A method of neutralizing the effect of AAA9 or a fragment thereof, comprising contacting an agent specific for said AAA9 or fragment thereof with said AAA9 or fragment thereof in an amount sufficient to effect neutralization.

19. A method of treating an angiogenesis disorder comprising administering to a patient an inhibitor of AAA9.

21. A method for localizing a therapeutic moiety to angiogenesis tissue comprising exposing said tissue to an antibody to AAA9 or fragment thereof conjugated to said therapeutic moiety.

22. The method of claim 21, wherein said therapeutic moiety is a cytotoxic agent.

23. The method of claim 21, wherein said therapeutic moiety is a radioisotope.

25. The method of claim 24, wherein said therapeutic moiety is a cytotoxic agent.

26. The method of claim 24, wherein said therapeutic moiety is a radioisotope.

24. A method of treating an angiogenesis disorder comprising administering to an individual having said angiogenesis disorder an antibody to AAA9 or fragment thereof conjugated to a therapeutic moiety.

27. A method for inhibiting angiogenesis in a cell, wherein said method comprises administering to a cell a composition comprising antisense molecules to a nucleic acid of FIG. 1.

28. A biochip comprising one or more nucleic acid segments encoding AAA9 or a fragment thereof, wherein said biochip comprises fewer than 1000 nucleic acid probes.

29. A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising AAA9 or a fragment thereof.

30. A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising a nucleic acid encoding AAA9 or a fragment thereof.

31. A method for determining the prognosis of an individual with an angiogenesis disorder comprising:

a) determining the expression of a gene encoding AAA9 or a fragment thereof in a first tissue type of a first individual; and

b) comparing said expression of said gene from a second normal tissue type from said first individual or a second unaffected individual;

wherein a substantial difference in said expression indicates a poor prognosis.